Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2017

Open Access 01-12-2017 | Research article

VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation

Authors: Yu Xie, Xiaodong Tan, Haiyan Shao, Qing Liu, Jiyu Tou, Yuling Zhang, Qiong Luo, Qunying Xiang

Published in: BMC Public Health | Issue 1/2017

Login to get access

Abstract

Background

Screening is the main preventive method for cervical cancer in developing countries, but each type of screening has advantages and disadvantages. To investigate the most suitable method for low-income areas in China, we conducted a health economic analysis comparing three methods: visual inspection with acetic acid and Lugol’s iodine (VIA/VILI), ThinPrep cytology test (TCT), and human papillomavirus (HPV) test.

Methods

We recruited 3086 women aged 35–65 years using cluster random sampling. Each participant was randomly assigned to one of three cervical cancer screening groups: VIA/VILI, TCT, or HPV test. In order to calculate the number of disability-adjusted life years (DALYs) averted by each screening method, we used Markov models to estimate the natural development of cervical cancer over a 15-year period to estimate the age of onset and duration of each disease stage. The cost-effectiveness ratios (CERs), net present values (NPVs), benefit-cost ratios (BCRs), and cost-utility ratios (CURs) were used as outcomes in the health economic analysis.

Results

The positive detection rate in the VIA/VILI group was 1.39%, which was 4.6 and 2.0 times higher than the rates in the TCT and HPV test groups, respectively. The positive predictive value of VIA/VILI (10.53%) was highest while the rate of referral for colposcopy was lowest for those in the HPV + TCT group (0.60%). VIA/VILI performed the best in terms of health economic evaluation results, as the cost of per positive case detected was 8467.9 RMB, which was 24503.0 RMB lower than that for TCT and 5755.9 RMB lower than that for the HPV test. In addition, the NPV and BCR values were 258011.5 RMB and 3.18 (the highest), and the CUR was 2341.8 RMB (the lowest). The TCT performed the worst, since its NPV was <0 and the BCR was <1, indicative of being poorly cost-beneficial.

Conclusions

With the best economic evaluation results and requiring minimum medical resources, VIA/VILI is recommended for cervical cancer screening in poverty-stricken areas in China with high incidence of cervical cancer and lack of medical resources.
Literature
1.
Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.CrossRefPubMed
2.
3.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12–23.CrossRefPubMed
4.
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 6:G1–31.CrossRefPubMed
5.
Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs. 2010;70(9):1079–98.CrossRefPubMed
6.
Bernard HU, Burk RD, Chen Z, van Doorslaer K, Zur HH, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–9.CrossRefPubMedPubMedCentral
7.
Boiron L, Joura E, Largeron N, Prager B, Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016;16(1):153.CrossRefPubMedPubMedCentral
8.
Gattoc L, Nair N, Ault K. Human papillomavirus vaccination: current indications and future directions. Obstet Gynecol Clin North Am. 2013;40(2):177–97.CrossRefPubMedPubMedCentral
9.
Centers for Disease Control. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626–9.
10.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.PubMed
11.
12.
13.
14.
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–101.CrossRefPubMed
15.
Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet. 2011;113(1):14–24.CrossRefPubMed
16.
Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111(1):167–77.CrossRefPubMed
17.
18.
Dong Z-W. Chinese guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Beijing: Peking University Medical Press; 2005.
19.
20.
Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol. 1986;67(5):665–9.CrossRefPubMed
21.
Denny L, Kuhn L, Pollack A, Wright TJ. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer. 2002;6:1699–707.CrossRef
22.
Li G-R. Application of Markov model in performance evaluation of cervical cancer screening. Chin J Health Stat. 2010;27(1):17–20.
23.
Xubin Bai. Economic Evaluation of the VIA/VILI Program--Early Diagnosis and Early Treatment of Cervical Cancer in the Countryside of Shanxi province. Taiyuan: Shanxi Medical University; 2009.
24.
25.
Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429–45.PubMedPubMedCentral
26.
LA Murray CJL. The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.
27.
Tang X, Qiao Y-L, Li G-R. Study on the method of determining the weight values in the calculation of DALYs. Chin J Health Stat. 2010;27(2):216–7.
28.
National Health and Family Planning Commission of the People’s Republic of China. Chinese Health and family planning statistical yearbook (2015). Beijing: Peking Union Medical College Press; 2016.
29.
Zeng M. Practice and thinking: hospital over the treatment and aid of a serious illness by NRCMS--Two cancer in women (breast cancer, cervical cancer), for example. Chin Health Ind. 2014;17:197–8.
30.
Liu Y-J, Zhang Q, Hu S-Y, Zhao F-H. Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. BMC Cancer. 2016;16:164.CrossRefPubMedPubMedCentral
31.
Salomon JA, Carvalho N, Gutierrez-Delgado C, Orozco R, Mancuso A, Hogan DR, et al. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ. 2012;344:e355.CrossRefPubMedPubMedCentral
32.
Ginsberg GM, Lauer JA, Zelle S, Baeten S, Baltussen R. Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e614.CrossRefPubMedPubMedCentral
33.
Hristina V, Sandra Š-G, Slavenka J, Jelena M, Nikola K, Ljiljana M-D, et al. Burden of Cancer in Serbia. Croat Med J. 2006;47:134–41.
34.
35.
36.
Mahe C, Gaffikin L. Screening test accuracy studies: how valid are our conclusions? Application to visual inspection methods for cervical screening. Cancer Causes Control. 2005;16(6):657–66.CrossRefPubMed
Metadata
Title
VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation
Authors
Yu Xie
Xiaodong Tan
Haiyan Shao
Qing Liu
Jiyu Tou
Yuling Zhang
Qiong Luo
Qunying Xiang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2017
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-017-4054-9

Other articles of this Issue 1/2017

BMC Public Health 1/2017 Go to the issue

Research article

Associations of multicultural status with depressive mood and suicidality among Korean adolescents: the roles of parental country of birth and socioeconomic position

Research article

Patients pathways to tuberculosis diagnosis and treatment in a fragmented health system: a qualitative study from a south Indian district

Research article

Association of informal caregiving with body mass index and frequency of sporting activities: evidence of a population-based study in Germany

Research article

Associations between measures of socio-economic status, beliefs about back pain, and exposure to a mass media campaign to improve back beliefs

Research article

The short-term health and psychosocial impacts of domestic energy efficiency investments in low-income areas: a controlled before and after study

Research article

Maternal blood cadmium, lead and arsenic levels, nutrient combinations, and offspring birthweight